Moleculin Biotech, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Moleculin Biotech amended and restated its 2024 Stock Plan effective October 24, 2024, with stockholder approval anticipated at the October 9, 2026 annual meeting. The plan authorizes 4,141,894 total shares (280,000 previously authorized plus 3,861,894 new shares) for grants to employees, directors, and consultants via stock options, stock awards, stock unit awards, and SARs. Annual individual grant limits are $1M for key employee/consultant options or SARs, $1M for stock/unit awards, and $500K for director awards (combined with cash fees). No specific grants, dollar amounts, or counterparties are disclosed in this plan document.
Why this rating
Routine equity plan amendment. At $8.8M market cap, 4.1M authorized shares is material dilution exposure, but plan mechanics are standard. No grants disclosed; no immediate cash outflow or business impact. Administrative filing.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.